D-serine in Schizophrenia

Last updated: October 9, 2018
Sponsor: Herzog Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Tourette's Syndrome

Psychosis

Mood Disorders

Treatment

N/A

Clinical Study ID

NCT03702933
HerzogHospital
  • Ages 18-55
  • All Genders

Study Summary

This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • DSM-5 Schizophrenia criteria, able and willing to give informed consent, and comply tostudy procedure, adequate contraception, post-menopausal or abstinent, PANSS TotalScore equal or greater than 70, score of 4 or greater on two psychotic items

Exclusion

Exclusion Criteria:

  • clinically significant, uncontrollable or unstable medical condition, mentalretardation or severe organic brain syndrome, significant risk of suicide or violentbehavior

Study Design

Total Participants: 40
Study Start date:
September 01, 2018
Estimated Completion Date:
December 01, 2021

Connect with a study center

  • Herzog Hospital

    Jerusalem, 91035
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.